Literature DB >> 22884069

Changes of regulatory T cells and FoxP3 gene expression in the aging process and its relationship with lung tumors in humans and mice.

Xu-Dong Pan1, Yan-Qing Mao, Li-Jing Zhu, Jie Li, Yan Xie, Ling Wang, Guang-Bo Zhang.   

Abstract

BACKGROUND: Immunosuppressive regulatory T cells (Tregs) participate in tumor immune evasion and the number and suppressive function of Tregs change with the aging process, but it is not clear whether such change leads to a higher incidence of tumors in the elderly. To this end, we designed experiments to explore the changes of Tregs and the functional gene Forkhead box P3 (FoxP3) in the aging process and its relationship with lung tumors in humans and mice.
METHODS: The percentage of CD4(+)CD25(+)CD127(low) Tregs and expression of FoxP3 mRNA were analyzed using flow cytometry (FCM) and real-time fluorescence-based quantitative polymerase chain reaction (FQ-PCR). Markers were analyzed in the peripheral blood (PB) of 65 elderly patients (age ≥ 65 years) with primary non-small cell lung cancer (NSCLC), 20 younger patients (aged < 55 years) with NSCLC, 30 elderly healthy individuals and 30 young healthy individuals. Furthermore, we set up the Lewis lung cancer model with C57BL/6 female mice. Thirty-six mice were divided into a young healthy group, a middle-aged healthy group, an elderly healthy group, a young tumor group, a middle-aged tumor group, and an elderly tumor group. The percentage of CD4(+)CD25(+)FoxP3(+) Tregs and the expression level of FoxP3 mRNA in splenocytes were determined in the six groups.
RESULTS: The percentage of peripheral CD4(+)CD25(+)CD127(low) Tregs and the expression of FoxP3 mRNA were significantly increased in elderly patients with NSCLC comparing with the other groups and in elderly healthy individuals compared with young healthy individuals. Further analysis showed that the percentage of CD4(+)CD25(+)CD127(low) Tregs and the expression of FoxP3 mRNA were closely associated with tumor node metastasis (TNM) staging in elderly patients with NSCLC. In the mouse model, the percentage of CD4(+)CD25(+)FoxP3(+) Tregs and the expression of FoxP3 mRNA in splenocytes of the tumor groups were significantly higher than in the healthy groups, with the highest expression in the elderly tumor group. In the healthy groups, the elderly healthy mice had the highest percentage of Tregs and expression of FoxP3 mRNA. The elderly mice had larger and heavier tumors than did the young and middle aged mice.
CONCLUSIONS: The up-regulation of Tregs and the FoxP3 gene with aging may play an essential role in oncogenesis and development of lung tumors in an elderly population.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22884069

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  9 in total

Review 1.  Immunosenescence: a key player in cancer development.

Authors:  Jingyao Lian; Ying Yue; Weina Yu; Yi Zhang
Journal:  J Hematol Oncol       Date:  2020-11-10       Impact factor: 17.388

Review 2.  Optimization of immunotherapy in elderly cancer patients.

Authors:  Kei Tomihara; Tyler J Curiel; Bin Zhang
Journal:  Crit Rev Oncog       Date:  2013

3.  Retrospective analysis of docetaxel in combination with ramucirumab for previously treated non-small cell lung cancer patients.

Authors:  Akihiro Yoshimura; Tadaaki Yamada; Yusuke Okuma; Rui Kitadai; Takayuki Takeda; Takanori Kanematsu; Hisatsugu Goto; Hiroto Yoneda; Taishi Harada; Yutaka Kubota; Takahiro Yamada; Koji Date; Shinsuke Shiotsu; Kazuhiro Nagata; Yusuke Chihara; Yoshiko Kaneko; Junji Uchino; Yasuhiko Nishioka; Koichi Takayama
Journal:  Transl Lung Cancer Res       Date:  2019-08

4.  Age matters:  Young T lymphocytes offer better protection from myeloma proliferation.

Authors:  Alexander F Glick; Yan S Song; Brian Hwang; John Lillvis; Pat Zanzonico; Camil Fuchs; Roger N Pearse; Paul Szabo; Marc E Weksler
Journal:  Immun Ageing       Date:  2013-02-18       Impact factor: 6.400

5.  Investigation of FOXP3 genetic variations at positions -2383 C/T and IVS9+459 T/C in southern Iranian patients with lung carcinoma.

Authors:  Maryam Fazelzadeh Haghighi; Mohammad Ali Ghayumi; Farzane Behzadnia; Nasrollah Erfani
Journal:  Iran J Basic Med Sci       Date:  2015-05       Impact factor: 2.699

6.  Prognostic value of circulating regulatory T cell subsets in untreated non-small cell lung cancer patients.

Authors:  Athanasios Kotsakis; Filippos Koinis; Afroditi Katsarou; Marianthi Gioulbasani; Despoina Aggouraki; Nikolaos Kentepozidis; Vassilis Georgoulias; Eleni-Kyriaki Vetsika
Journal:  Sci Rep       Date:  2016-12-15       Impact factor: 4.379

7.  PD-L1 Expression Is Associated with FOXP3+ Regulatory T-Cell Infiltration of Soft Tissue Sarcoma and Poor Patient Prognosis.

Authors:  Yi Que; Wei Xiao; Yuan-Xiang Guan; Yao Liang; Shu-Mei Yan; Huo-Ying Chen; Qiao-Qiao Li; Bu-Shu Xu; Zhi-Wei Zhou; Xing Zhang
Journal:  J Cancer       Date:  2017-07-05       Impact factor: 4.207

8.  Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study.

Authors:  Akihiro Yoshimura; Tadaaki Yamada; Yusuke Okuma; Akito Fukuda; Satoshi Watanabe; Naoya Nishioka; Takayuki Takeda; Yusuke Chihara; Shinnosuke Takemoto; Taishi Harada; Osamu Hiranuma; Yukina Shirai; Akihiro Nishiyama; Seiji Yano; Yasuhiro Goto; Shinsuke Shiotsu; Kei Kunimasa; Yoshie Morimoto; Masahiro Iwasaku; Yoshiko Kaneko; Junji Uchino; Hirotsugu Kenmotsu; Toshiaki Takahashi; Koichi Takayama
Journal:  Transl Lung Cancer Res       Date:  2021-08

9.  Age-related autoimmunity.

Authors:  Zahava Vadasz; Tharwat Haj; Aharon Kessel; Elias Toubi
Journal:  BMC Med       Date:  2013-04-04       Impact factor: 8.775

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.